EIF4A1: A Drug Target / Disease Biomarker (G1973)

Target Name: EIF4A1

NCBI ID: G1973

EIF4A1

EIF4A1: A Drug Target / Disease Biomarker

EIF4A1, also known as EIF4A, is a protein that is expressed in various tissues of the body, including the brain, heart, and lungs. It is a member of the EIF4 family, which includes several similar proteins that play a role in the regulation of cell signaling pathways. One of the unique features of EIF4A1 is its ability to interact with the protein p180GAP, which is a key regulator of theMAPK/ERK signaling pathway. This interaction between EIF4A1 and p180GAP has led to the suggestion that EIF4A1 may be a drug target or biomarker for the treatment of various diseases.

The MAPK/ERK signaling pathway is a critical pathway that regulates various cellular processes, including cell growth, differentiation, and response to stimuli. The MAPK/ERK signaling pathway is activated by the recruitment of several protein kinases, including p180GAP. p180GAP is a protein that is involved in the regulation of several cellular processes, including the regulation of cell signaling pathways, cell adhesion, and cell survival.

EIF4A1 is able to interact with p180GAP in a way that allows it to regulate the activity of p180GAP. This interaction between EIF4A1 and p180GAP has led to the suggestion that EIF4A1 may be a drug target or biomarker for the treatment of diseases that are characterized by the disruption of the MAPK/ERK signaling pathway.

One of the potential benefits of targeting EIF4A1 is its potential to treat a variety of diseases. For example, EIF4A1 has been suggested as a potential therapeutic target for the treatment of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and the progressive decline in cognitive function that follows.

EIF4A1 has also been suggested as a potential therapeutic target for the treatment of other diseases, including cancer, cardiovascular disease, and respiratory disease. For example, studies have suggested that EIF4A1 may be involved in the regulation of cell signaling pathways that are altered in many types of cancer. Additionally, EIF4A1 has been suggested as a potential biomarker for the diagnosis and prognosis of cardiovascular disease.

In addition to its potential therapeutic applications, EIF4A1 also has significant interest in the study of its biology and its role in various cellular processes. The regulation of the MAPK/ERK signaling pathway by EIF4A1 has led to a better understanding of the mechanisms that regulate cell signaling pathways. Additionally, the study of EIF4A1 has also led to the development of new techniques for the analysis of protein-protein interactions and the regulation of cellular signaling pathways.

Overall, EIF4A1 is a protein that has significant potential as a drug target or biomarker for the treatment of various diseases. The regulation of the MAPK/ERK signaling pathway by EIF4A1 has led to a better understanding of the mechanisms that regulate cell signaling pathways, and the study of EIF4A1 has also led to the development of new techniques for the analysis of protein-protein interactions. Further research is needed to fully understand the potential therapeutic applications of EIF4A1 and to develop effective treatments for the diseases associated with its disruption.

Protein Name: Eukaryotic Translation Initiation Factor 4A1

Functions: ATP-dependent RNA helicase which is a subunit of the eIF4F complex involved in cap recognition and is required for mRNA binding to ribosome. In the current model of translation initiation, eIF4A unwinds RNA secondary structures in the 5'-UTR of mRNAs which is necessary to allow efficient binding of the small ribosomal subunit, and subsequent scanning for the initiator codon

The "EIF4A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EIF4A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets